Table 3.

Hepatic dendritic cells’ (CD11c ⁺ ) expression in MAFLD according to patients’ BMI and either presence or absence of fibrosis:

The findings of liver fibrosis among different weight groups was variable, finding that the most marked difference is dependent on the number of patients in each group (eg, non-obese patients constitute a lower percentage of the population, for which they constitute a lower percentage of patients with fibrosis, as well as without fibrosis).

Patients with MAFLD (n=128)	Hepatic dendritic cells (CD11c+) N (%) 72
Morbidly obese patients with no fibrosis (n=44)	29 (65.91)
Morbidly obese patients with fibrosis (n=32)	20 (62.50)
Patients with obesity grade I–II and no fibrosis (n=13)	8 (61.54)
Patients with obesity grade I–II and fibrosis (n=20)	10 (50.00)
Non-obese patients with no fibrosis (n=7)	2 (28.57)
Non-obese patients with fibrosis (n=12)	3 (25.00)

BMI – body mass index; MAFLD – metabolic (dysfunction)-associated fatty liver disease.